drugset / Trial / NCT05803850
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058
RandomizedSequentialQuadruple-blindTreatment
Summary
The purpose of this First-in-Human study is to evaluate the safety and tolerability after single ascending oral doses of HNC1058 given to healthy subjects, compared to placebo.
Timeline
- Start
- 2023-03-28
- Primary completion
- 2024-02-27
- Completion
- 2024-03-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HNC1058 | Unknown | 10 mg | Oral |
| Subject | HNC1058 | Unknown | 50 mg | Oral |
| Subject | HNC1058 | Unknown | 80 mg | Oral |